

**SUMMARY OF CHANGES:**

**INSTRUMENT NOS. 1 to 16 of 2019**

Statements of Principles Nos. 1 to 16 of 2019 were signed by the Chairperson of the Repatriation Medical Authority (the Authority) on 21 December 2018.

The Instruments have been lodged and registered with the Federal Register of Legislation, pursuant to section 15G of the *Legislation Act 2003* (Legislation Act). The day of commencement is specified in each of the Statements of Principles. Instrument Nos. 1 to 14 of 2019 have a day of commencement of 28 January 2019. Instrument Nos. 15 and 16 of 2019 (Amendment Statements of Principles concerning localised sclerosis) have a day of commencement of 23 July 2018. In accordance with the Legislation Act, the Office of Parliamentary Counsel must generally deliver a legislative instrument for laying before each House of the Parliament within six sitting days of that House after the instrument is registered with the instrument's registered explanatory statement. The Instruments and the associated Explanatory Statements registered with the Federal Register of Legislation are available from [http://www.legislation.gov.au](http://www.comlaw.gov.au).

Copies of each Instrument, the associated Explanatory Statement and a list of references relating to each Statement of Principles, are available in accordance with the *Veterans' Entitlements Act 1986* (the VEA), on written request from the RMA Secretariat.

The 'User Guide to the RMA Statements of Principles' explains the meaning and purpose of each section of the new Statement of Principles template which commenced in 2015. This document is available on the Authority's website at <http://www.rma.gov.au>.

For further information contact:

The Registrar

Repatriation Medical Authority

GPO Box 1014

Brisbane Qld 4001

T +61 7 3815 9404

F +61 7 3815 9412

E info@rma.gov.au

4 January 2019

**SUMMARY OF CHANGES**

|  |  |  |  |
| --- | --- | --- | --- |
| **Instr. No.** | **Title** | **Date of Commencement** | **ICD-10-AM Code** |
| **REVOCATIONS** |
|  |  |  |  |
| 1 & 2/2019 | chondromalacia patella | 28/01/2019 | M22.4 |
|  |  |  |  |
| 3 & 4/2019 | iliotibial band syndrome | 28/01/2019 | M76.3 |
|  |  |  |  |
| 5 & 6/2019 | human immunodeficiency virus infection | 28/01/2019 | B20, B21, B22, B23, B24 or Z21 |
|  |  |  |  |
| 7 & 8/2019 | internal derangement of the knee | 28/01/2019 | M23.2, M23.5, M23.8 or M23.9 |
|  |  |  |  |
| 9 & 10/2019 | Dupuytren disease | 28/01/2019 | M72.0 |
|  |  |  |  |
| 11 & 12/2019 | hypopituitarism | 28/01/2019 | E23.0 |
|  |  |  |  |
| **AMENDMENTS** |
|  |  |  |  |
| 13 & 14/2019 | sarcoidosis | 28/01/2019 | N/A |
|  |  |  |  |
| 15 & 6/2019 | localised sclerosis | 23/07/2018 | N/A |
|  |  |  |  |

**Note:**

The investigation concerning 'Dupuytren's disease' has resulted in the determination of Statements of Principles concerning **Dupuytren disease**.

The investigation concerning 'human immunodeficiency virus' has resulted in the determination of Statements of Principles concerning **human immunodeficiency virus infection**.

As a result of becoming aware of typographical errors in each of the Statements of Principles concerning localised sclerosis determined at the June 2018 RMA meeting, the Authority determined to correct the Statements of Principles with the amendments above.

| **SUMMARY OF CHANGES** |
| --- |
| 1 & 2/2019 | chondromalacia patella | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 14 November 2017 concerning *chondromalacia patella* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 1/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'chondromalacia patella' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factors in subsections 9(1) & 9(9) concerning 'direct trauma to the patella';
* revising the factors in subsections 9(2) & 9(10) concerning 'patellar dislocation';
* revising the factors in subsections 9(3) & 9(11) concerning 'injury to the affected knee';
* revising the factors in subsections 9(4) & 9(12) concerning 'acquired abnormal tracking of the patella', by the inclusion of a note;
* revising the factors in subsections 9(5) & 9(13) concerning 'running or jogging';
* revising the factors in subsections 9(6) & 9(14) concerning 'weight bearing exercise';
* revising the factors in subsections 9(7) & 9(15) concerning 'increasing the frequency, duration or intensity of weight bearing activity';
* new factors in subsections 9(8) & 9(16) concerning 'being obese';
* new definitions of 'being obese', 'BMI', 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and
* revising the definition of 'relevant service' in Schedule 1 - Dictionary.

***For BoP SoP*** ***(Instrument No. 2/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'chondromalacia patella' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factors in subsections 9(1) & 9(8) concerning 'direct trauma to the patella';
* revising the factors in subsections 9(2) & 9(9) concerning 'patellar dislocation';
* revising the factors in subsections 9(3) & 9(10) concerning 'injury to the affected knee';
* revising the factors in subsections 9(4) & 9(11) concerning 'acquired abnormal tracking of the patella', by the inclusion of a note;
* revising the factors in subsections 9(5) & 9(12) concerning 'running or jogging';
* revising the factors in subsections 9(6) & 9(13) concerning 'weight bearing exercise';
* revising the factors in subsections 9(7) & 9(14) concerning 'increasing the frequency, duration or intensity of weight bearing activity';
* new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary;
* revising the definition of 'relevant service' in Schedule 1 - Dictionary.

**The determining of these Instruments finalises the investigation in relation to *chondromalacia patella* as advertised in the Government Notices Gazette of 14 November 2017.** |
| 3 & 4/2019 | iliotibial band syndrome | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 14 November 2017 concerning *iliotibial band syndrome* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 3/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'iliotibial band syndrome' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factors in subsections 9(1) & 9(9) concerning 'running or jogging';
* revising the factors in subsections 9(2) & 9(10) concerning 'weight bearing exercise';
* revising the factors in subsections 9(3) & 9(11) concerning 'increasing the frequency, duration or intensity of weight bearing activity';
* new factors in subsections 9(4) & 9(12) concerning 'cycling';
* new factors in subsections 9(5) & 9(13) concerning 'increasing the frequency, duration, or intensity of cycling';
* new factors in subsections 9(6) & 9(14) concerning 'knee reconstruction surgery';
* new factors in subsections 9(7) & 9(15) concerning 'weakness or paralysis of an abductor muscle of the hip';
* new factors in subsections 9(8) & 9(16) concerning 'varus malalignment of the knee or varus thrust of the knee';
* new definitions of 'MRCA', 'varus malalignment of the knee', 'varus thrust of the knee' and 'VEA' in Schedule 1 - Dictionary; and
* revising the definition of 'relevant service' in Schedule 1 - Dictionary.

***For BoP SoP*** ***(Instrument No. 4/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'iliotibial band syndrome' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factors in subsections 9(1) & 9(7) concerning 'running or jogging';
* revising the factors in subsections 9(2) & 9(8) concerning 'weight bearing exercise';
* revising the factors in subsections 9(3) & 9(9) concerning 'increasing the frequency, duration or intensity of weight bearing activity';
* new factors in subsections 9(4) & 9(10) concerning 'cycling';
* new factors in subsections 9(5) & 9(11) concerning 'increasing the frequency, duration, or intensity of cycling';
* new factors in subsections 9(6) & 9(12) concerning 'knee reconstruction surgery';
* new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and
* revising the definition of 'relevant service' in Schedule 1 - Dictionary.

**The determining of these Instruments finalises the investigation in relation to *iliotibial band syndrome* as advertised in the Government Notices Gazette of 14 November 2017.** |
| 5 & 6/2019 | human immunodeficiency virus infection | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning *human immunodeficiency virus* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 5/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* changing the title of the Instrument to 'human immunodeficiency virus infection';
* revising the definition of 'human immunodeficiency virus infection' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning 'being exposed to HIV-1 or HIV-2';
* new factor in subsection 9(2) concerning 'genital ulcerative disease' or 'non ulcerative anogenital sexually transmitted infection' or 'herpes simplex virus type 2 anogential infection';
* new factor in subsection 9(3) concerning 'depot medroxyprogesterone acetate contraception';
* revising the factor in subsection 9(4) concerning 'an infection from the specified list';
* new definitions of 'helminthic infection', 'MRCA', 'specified list of infections' and 'VEA' in Schedule 1 - Dictionary; and
* revising the definitions of 'being exposed to HIV-1 or HIV-2', 'relevant service' and 'specified body substance' in Schedule 1 - Dictionary.

***For BoP SoP*** ***(Instrument No. 6/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* changing the title of the Instrument to 'human immunodeficiency virus infection';
* revising the definition of 'human immunodeficiency virus infection' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factor in subsection 9(1) concerning 'being exposed to HIV-1 or HIV-2';
* new factor in subsection 9(2) concerning 'a genital ulcerative disease' or 'non ulcerative anogenital sexually transmitted infection' or 'herpes simplex virus type 2 anogential infection';
* new factor in subsection 9(3) concerning 'depot medroxyprogesterone acetate contraception';
* new factor in subsection 9(4) concerning 'tuberculosis';
* new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and
* revising the definitions of 'being exposed to HIV-1 or HIV-2', 'relevant service' and 'specified body substance' in Schedule 1 - Dictionary.

**The determining of these Instruments finalises the investigation in relation to *human immunodeficiency virus* as advertised in the Government Notices Gazette of 19 October 2016.** |
| 7 & 8/2019 | internal derangement of the knee | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 14 November 2017 concerning *internal derangement of the knee* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH & BoP SoPs*** ***(Instrument Nos. 7 & 8/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'internal derangement of the knee' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factors in subsections 9(1) & 9(3) concerning 'sprain';
* revising the factors in subsections 9(2) & 9(4) concerning 'acute meniscal tear';
* new definitions of 'MRCA' and 'VEA' in Schedule 1 - Dictionary; and
* revising the definition of 'relevant service' in Schedule 1 - Dictionary.

**The determining of these Instruments finalises the investigation in relation to *internal derangement of the knee* as advertised in the Government Notices Gazette of 14 November 2017.**  |
| 9 & 10/2019 | Dupuytren disease | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 14 November 2017 concerning *Dupuytren's disease* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 9/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* changing the title of the Instrument to 'Dupuytren disease';
* revising the definition of 'Dupuytren disease' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factors in subsections 9(1) & 9(14) concerning 'smoking';
* revising the factors in subsections 9(2) & 9(15) concerning 'alcohol';
* new factors in subsections 9(3) & 9(16) concerning 'alcohol use disorder';
* revising the factors in subsections 9(4) & 9(17) concerning 'cirrhosis of the liver or steatohepatitis';
* revising the factors in subsections 9(5) & 9(18) concerning 'trauma';
* revising the factors in subsections 9(6) & 9(19) concerning 'infection';
* revising the factors in subsections 9(7)(a) & 9(20)(a) concerning 'trauma', for bilateral Dupuytren disease only;
* revising the factors in subsections 9(7)(b) & 9(20)(b) concerning 'infection', for bilateral Dupuytren disease only;
* revising the factors in subsections 9(8) & 9(21) concerning 'repetitive, strenuous or forceful activities' or 'activities using a hand-held, vibrating or percussive tool';
* revising the factors in subsections 9(9) & 9(22) concerning 'diabetes mellitus';
* new factors in subsections 9(10) & 9(23) concerning 'epilepsy';
* new factors in subsections 9(11) & 9(24) concerning 'psoriasis';
* new factors in subsections 9(12) & 9(25) concerning 'vemurafenib';
* new factors in subsections 9(13) & 9(26) concerning 'phenobarbital';
* new definitions of 'clinically significant infection involving the palmar surface of the affected hand', 'MRCA' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'pack-years of cigarettes, or the equivalent thereof in other tobacco products', 'relevant service' and 'trauma' in Schedule 1 - Dictionary; and
* deleting the definitions of 'alcohol', 'alcoholic liver disease', 'an infection of the hand as specified' and 'tasks involving manual labour'.

***For BoP SoP*** ***(Instrument No. 10/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* changing the title of the Instrument to 'Dupuytren disease';
* revising the definition of 'Dupuytren disease' in subsection 7(2);
* revising the reference to 'ICD-10-AM code' in subsection 7(4);
* revising the factors in subsections 9(1) & 9(12) concerning 'smoking';
* revising the factors in subsections 9(2) & 9(13) concerning 'alcohol';
* new factors in subsections 9(3) & 9(14) concerning 'alcohol use disorder';
* revising the factors in subsections 9(4) & 9(15) concerning 'alcoholic liver disease';
* revising the factors in subsections 9(5) & 9(16) concerning 'trauma';
* revising the factors in subsections 9(6) & 9(17) concerning 'infection';
* new factors in subsections 9(7)(a) & 9(18)(a) concerning 'trauma', for bilateral Dupuytren disease only;
* new factors in subsections 9(7)(b) & 9(18)(b) concerning 'infection', for bilateral Dupuytren disease only;
* new factors in subsections 9(8) & 9(19) concerning 'repetitive, strenuous or forceful activities' or 'activities using a hand-held, vibrating or percussive tool';
* new factors in subsections 9(9) & 9(20) concerning 'diabetes mellitus';
* new factors in subsections 9(10) & 9(21) concerning 'epilepsy';
* new factors in subsections 9(11) & 9(22) concerning 'vemurafenib';
* new definitions of 'clinically significant infection involving the palmar surface of the affected hand', 'MRCA' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'pack-years of cigarettes, or the equivalent thereof in other tobacco products', 'relevant service' and 'trauma' in Schedule 1 - Dictionary; and
* deleting the definitions of 'alcohol' and 'an infection of the hand as specified'.

**The determining of these Instruments finalises the investigation in relation to *Dupuytren's disease* as advertised in the Government Notices Gazette of 14 November 2017.** |
| 11 & 12/2019 | hypopituitarism | These Instruments result from an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning *hypopituitarism* in accordance with section 196G of the VEA. The investigation involved an examination of the sound medical-scientific evidence now available to the Authority, including the sound medical-scientific evidence it has previously considered.The contents of these Instruments are in similar terms as the repealed Instruments. Comparing these Instruments and the repealed Instruments, the differences include:***For RH SoP*** ***(Instrument No. 11/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'hypopituitarism' in subsection 7(2);
* including ICD-10-AM codes for 'hypopituitarism' in subsection 7(3);
* revising the factors in subsections 9(2) & 9(20) concerning 'a disorder from the specified list of infiltrative, inflammatory or granulomatous disorders, involving the pituitary gland or hypothalamus';
* revising the factors in subsections 9(3) & 9(21) concerning 'human immunodeficiency virus';
* revising the factors in subsections 9(4) & 9(22) concerning 'a viral, bacterial, fungal or protozoal infection of the pituitary gland, hypothalamus, brain or cerebral meninges';
* revising the factors in subsections 9(5) & 9(23) concerning 'Hantavirus haemorrhagic fever with renal syndrome';
* revising the factors in subsections 9(6) & 9(24) concerning 'moderate to severe traumatic brain injury';
* new factors in subsections 9(7) & 9(25) concerning 'concussion';
* new factors in subsections 9(8) & 9(26) concerning 'high impact contact activity involving blows to the head';
* revising the factors in subsections 9(10) & 9(28) concerning 'haemorrhage or ischaemia involving the pituitary or hypothalamus';
* revising the factors in subsections 9(11) & 9(29) concerning 'severe peripartum or postpartum haemorrhage';
* revising the factors in subsections 9(12) & 9(30) concerning 'cerebral oedema from diabetic ketoacidosis';
* revising the factors in subsections 9(13) & 9(31) concerning 'surgery involving the pituitary gland, or intracranial surgery';
* revising the factors in subsections 9(14) & 9(32) concerning 'therapeutic radiation for cancer';
* revising the factors in subsections 9(16) & 9(34) concerning 'immune checkpoint inhibitor, or an interferon';
* new factors in subsections 9(18) & 9(36) concerning 'being pregnant', for lymphocytic hypophysitis only;
* new definitions of 'blows to the head', 'Hantavirus haemorrhagic fever with renal syndrome', 'high impact contact activity', 'immune checkpoint inhibitor', 'lymphocytic hypophysitis', 'MRCA', 'specified list of infiltrative, inflammatory or granulomatous disorders' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'iron overload' and 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a course of therapeutic radiation', 'cerebral trauma' and 'infiltration of pituitary gland or hypothalamus due to a specified disorder'.

***For BoP SoP*** ***(Instrument No. 12/2019)**** adopting the latest revised Instrument format, which commenced in 2015;
* specifying a day of commencement for the Instrument in section 2;
* revising the definition of 'hypopituitarism' in subsection 7(2);
* including ICD-10-AM codes for 'hypopituitarism' in subsection 7(3);
* revising the factors in subsections 9(2) & 9(16) concerning 'a disorder from the specified list of infiltrative, inflammatory or granulomatous disorders, involving the pituitary gland or hypothalamus';
* revising the factors in subsections 9(3) & 9(17) concerning 'human immunodeficiency virus';
* revising the factors in subsections 9(4) & 9(18) concerning 'a viral, bacterial, fungal or protozoal infection of the pituitary gland, hypothalamus, brain or cerebral meninges';
* revising the factors in subsections 9(5) & 9(19) concerning 'Hantavirus haemorrhagic fever with renal syndrome';
* revising the factors in subsections 9(6) & 9(20) concerning 'moderate to severe traumatic brain injury';
* revising the factors in subsections 9(8) & 9(22) concerning 'haemorrhage or ischaemia involving the pituitary or hypothalamus';
* revising the factors in subsections 9(9) & 9(23) concerning 'severe peripartum or postpartum haemorrhage';
* revising the factors in subsections 9(10) & 9(24) concerning 'surgery involving the pituitary gland, or intracranial surgery';
* revising the factors in subsections 9(11) & 9(25) concerning 'therapeutic radiation for cancer';
* revising the factors in subsections 9(13) & 9(27) concerning 'immune checkpoint inhibitor, or an interferon';
* new factors in subsections 9(14) & 9(28) concerning 'being pregnant', for lymphocytic hypophysitis only;
* deleting the factors concerning 'cerebral oedema from diabetic ketoacidosis' and 'regularly using intranasal cocaine such that there is destruction of the nasal septum, palate or paranasal sinuses';
* new definitions of 'Hantavirus haemorrhagic fever with renal syndrome', 'immune checkpoint inhibitor', 'lymphocytic hypophysitis', 'MRCA', 'specified list of infiltrative, inflammatory or granulomatous disorders' and 'VEA' in Schedule 1 - Dictionary;
* revising the definitions of 'iron overload' and 'relevant service' in Schedule 1 - Dictionary; and
* deleting the definitions of 'a course of therapeutic radiation', 'cerebral trauma' and 'infiltration of pituitary gland or hypothalamus due to a specified disorder'.

On 10 August 2018, the Authority wrote to organisations representing veterans, service personnel and their dependants regarding the proposed Instruments and the medical-scientific material considered by the Authority. This letter emphasised the deletion of factors from the Balance of Probabilities Statement of Principles relating to ***cerebral oedema from diabetic ketoacidosis*** and ***regularly using intranasal cocaine such that there is destruction of the nasal septum, palate or paranasal sinuses***. The Authority provided an opportunity to the organisations to make representations in relation to the proposed Instruments prior to their determination. No submissions were received for consideration by the Authority. Minor changes were made to the proposed Instruments following this consultation process.**The determining of these Instruments finalises the investigation in relation to *hypopituitarism* as advertised in the Government Notices Gazette of 19 October 2016.** |
| 13 & 14/2019 | sarcoidosis | **Amendment**These instruments amend Statements of Principles Nos. 59 & 60 of 2016 concerning ***sarcoidosis*** by:***For RH Amendment SoP*** ***(Instrument No. 13/2019)**** replacing the existing factors in subsections 9(1) & 9(6) concerning 'being treated with a drug';
* inserting new factors in subsections 9(1a) & 9(6a) concerning 'immunotherapy for cancer or targeted therapy for cancer';
* inserting new factors in subsections 9(3a) & 9(8a) concerning 'malignant neoplasm'; and
* inserting definitions of 'immunotherapy for cancer', 'specified list of drugs' and 'targeted therapy for cancer' in Schedule 1 - Dictionary; and
* specifying the day of commencement of these amendments.

***For BoP Amendment SoP*** ***(Instrument No. 14/2019)**** replacing the existing factors in subsections 9(1) & 9(3) concerning 'being treated with a drug';
* inserting a definition of 'specified list of drugs' in Schedule 1 - Dictionary; and
* specifying the day of commencement of these amendments.

**The determining of these Instruments finalises the investigation in relation to *sarcoidosis* as advertised in the Government Notices Gazette of 4 September 2018.** |
| 15 & 16/2019 | localised sclerosis | **Amendment**These instruments amend Statements of Principles Nos. 61 & 62 of 2018 concerning ***localised sclerosis*** by:***For RH Amendment SoP*** ***(Instrument No. 15/2019)**** amending typographical errors in the subject of two factors in the Statement of Principles. In particular, in subsections 9(2) & 9(5) concerning 'being treated with a drug or a drug from a class of drugs', replacing "systemic sclerosis" with "localised sclerosis"; and
* specifying the day of commencement of these amendments.

***For BoP Amendment SoP*** ***(Instrument No. 16/2019)**** amending typographical errors in the subject of two factors in the Statement of Principles. In particular, in subsections 9(1) & 9(3) concerning 'being treated with a drug or a drug from a class of drugs', replacing "systemic sclerosis" with "localised sclerosis"; and
* specifying the day of commencement of these amendments.

**The amended Statements of Principles will now accurately reflect the results of an investigation notified by the Authority in the Government Notices Gazette of 19 October 2016 concerning *localised sclerosis* in accordance with section 196G of the VEA. The determining of Statements of Principles Instrument Nos. 61 & 62 of 2018 and Amendment Statements of Principles Instrument Nos. 15 & 16 of 2019 finalises the investigation in relation to *localised sclerosis* as advertised in the Government Notices Gazette of 19 October 2016.** |